Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods

Patent metadata

Field	Value
Publication number	US-9579341-B2
Application number	US-201314086548-A
Country	US
Kind code	B2
Filing date	Nov 21, 2013
Priority date	May 16, 2007
Publication date	Feb 28, 2017
Grant date	Feb 28, 2017

Abstract

The invention provides a composition containing hyaluronic acid (HA) or a pharmaceutically-acceptable salt thereof preserved with a cationic preservative and related methods. In one embodiment, the pharmaceutically-acceptable salt is sodium hyaluronate. In another embodiment, the cationic preservative includes benzalkonium.

First claim

What is claimed is:

1. A method for preparing a preserved hyaluronic acid composition, the method consisting essentially of:
dissolving a cationic preservative which is poly[oxyethylene(dimethyliminio)ethylene(dimethyliminio)ethylenedichloride] in a first quantity of a solvent;
dissolving a quantity of hyaluronic acid (HA) or physiologically-acceptable salt thereof in a second quantity of the solvent wherein the ratio of the first quantity of solvent to the second quantity of solvent is between 1.8:1 and 2.2:1; and
adding the dissolved HA or physiologically-acceptable salt thereof to the dissolved cationic preservative,
wherein precipitation of the cationic preservative and the HA or physiologically-acceptable salt thereof is substantially prevented by preparing separate HA or physiologically-acceptable salt thereof and separate cationic preservative solutions which are then combined.

2. The method of claim 1 , wherein the physiologically-acceptable salt of HA includes sodium hyaluronate.

3. The method of claim 1 , wherein the HA has a molecular weight between about 500,000 daltons and about 4,000,000 daltons.

4. The method of claim 3 , wherein the molecular weight is between about 1,000,000 daltons and about 2,000,000 daltons.

5. The method of claim 1 , wherein the solvent includes water.

6. The method of claim 5 , wherein the solvent further consists essentially of at least one of the following: glycerin, polyethylene glycol (PEG), and propylene glycol.

7. The method of claim 1 , wherein a ratio of the first quantity of the solvent to the second quantity of the solvent is between about 1.8:1 and about 2.2:1.

8. The method of claim 7 , wherein the ratio is about 2:1.

9. The method of claim 1 , further consisting essentially of:
filtering the combined HA or physiologically-acceptable salt thereof and cationic preservative solution.

10. The method of claim 9 , wherein the HA or physiologically-acceptable salt thereof and cationic preservative solution has a transmittance between about 93% and about 98% at 440 nm before filtration.

11. The method of claim 9 , wherein the combined HA or physiologically-acceptable salt thereof and cationic preservative solution has a transmittance between about 95% and about 100% at 440 nm after filtration.

12. The method of claim 1 , wherein the composition has a concentration of unprecipitated HA between about 0.1% and about 0.5%.

13. A composition prepared according to the method of claim 1 .

14. A method for preparing a preserved hyaluronic acid composition, the method consisting essentially of:
dissolving a cationic preservative which is poly[oxyethylene(dimethyliminio)ethylene(dimethyliminio)ethylenedichloride] in a first quantity of a solvent;
dissolving a quantity of hyaluronic acid (HA) or physiologically-acceptable salt thereof in a second quantity of the solvent wherein the ratio of the first quantity of solvent to the second quantity of solvent is between 1.8:1 and 2.2:1;
dissolving a quantity of an anionic cellulose derivative in a third quantity of the solvent;
adding the dissolved HA or physiologically-acceptable salt thereof to the dissolved cationic preservative; and
adding the dissolved anionic cellulose derivative to at least one of the following: the dissolved HA or physiologically-acceptable salt thereof, the dissolved cationic preservative, and the combined dissolved HA or physiologically-acceptable salt thereof and cationic preservative,
wherein precipitation of the cationic preservative and the HA or physiologically-acceptable salt thereof is substantially prevented by preparing separate HA or physiologically-acceptable salt thereof and separate cationic preservative solutions which are then combined.

Assignees

• Johnson & Johnson Consumer Inc

Inventors

• Doshi Uday
• Holeva Kenneth T

Classifications

• C07C279/26

  X and Y being nitrogen atoms, i.e. biguanides · CPC title

• C08B37/0072

  Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates · CPC title

• A61K31/728 Primary

  Hyaluronic acid · CPC title

• A61K47/18

  Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids · CPC title

• A61K9/0043

  Nose · CPC title